AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-74. (cancelled)

75. (previously presented) The delayed-release formulation according to Claim 95, wherein said delayed-release formulation has a thin and elongated form with a diameter not exceeding 3mm.

76. (previously presented) The delayed-release formulation according to Claim 75, wherein said delayed-release formulation has a diameter not exceeding 2 mm.

77. (previously presented) The delayed-release formulation according to Claim 75, wherein said delayed-release formulation has a diameter of the order of 0.1 mm.

78. (previously presented) The delayed-release formulation according to Claim 98, wherein said delayed-release formulation has a minimum length/diameter ratio of 10.

79. (canceled)

80. (currently amended) A solid delayed-release formulation for parenteral administration through an invasive device delivering said formulation in a body comprising a homogeneous mixture of an active principle wherein the active

principle is a proteic or peptidic active principle other than insulin, in a non-dispersed state forming a continuous phase of which at least one part is in direct contact with the exchange surface of the formulation and of the exterior biological medium, and of a biodegradable biocompatible excipient, in which the quantity of active principle is ~~at least 50%~~ above 50% and less than or equal to 80% by weight with respect to the total weight of the formulation, and having a release profile which is independent of the composition of the excipient, of the molecular weight of the excipient or of the active principle/excipient weight ratio, the release profile being substantially dependent on the total quantity of active principle present in the formulation.

81. (previously presented) The delayed-release formulation according to Claim 80, wherein the biodegradable biocompatible excipient is a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic and/or glycolic acid.

82. (previously presented) The delayed-release formulation according to Claim 81, wherein the said biodegradable biocompatible polymer is a copolymer of lactic acid and glycolic acid (PLGA).

83. (previously presented) The delayed-release formulation according to Claim 80, wherein the said biodegradable biocompatible polymer is a copolymer of lactic and glycolic acid

having an intrinsic viscosity in chloroform at 1 g per 100 ml of greater than 0.6 dl/g.

84. (previously presented) The delayed-release formulation according to Claim 82, wherein the copolymer of lactic acid and glycolic acid is of hydrophilic nature.

85. (previously presented) The delayed-release formulation according to Claim 80, wherein when said delayed-release formulation is placed *in vitro* in a physiological liquid medium, said delayed-release formulation liberates almost the whole of the active principle in less than a week, and, when said delayed-release formulation is placed *in vivo* subcutaneously or intramuscularly, has a release of active principle over a period substantially greater than one week.

86. (previously presented) The delayed-release formulation according to Claim 80, wherein said delayed-release formulation comprises a mixture of the active principle and the excipient which is homogenous at all points.

87. (previously presented) The delayed-release formulation according to Claim 80, wherein the release takes place in a single diffusion phase of the active principle.

88. (previously presented) The delayed-release formulation according to Claim 80, wherein the active principle represents at least 51% by weight with respect to the total weight of the formulation, the excipient representing less than 50% by weight with respect to the total weight of the formulation.

89. (previously presented) The delayed-release formulation according to Claim 80, wherein the active principle is selected from the group consisting of a peptide, a peptide analogue, a protein, Luteinizing Hormone-Releasing Factor (LHRH), an analogue of LHRH, and triptorelin.

90. (previously presented) The delayed-release formulation according to Claim 80, wherein said delayed-release formulation is in cylindrical form and has a diameter less than or equal to 3 mm.

91. (previously presented) The delayed-release formulation according to Claim 80, adapted for injection by the intramuscular or subcutaneous route.

92. (previously presented) The delayed-release formulation according to Claim 80, wherein said delayed-release formulation is in the form of an implant.

93. (previously presented) A process for preparation of a delayed-release formulation according to Claim 80, comprising the steps:

- producing a homogeneous mixture of the active principle and the excipient, containing at least 50% of active principle;
- compacting the said mixture; and
- extruding the said compacted mixture in the molten state.

94. (previously presented) A process for preparation of a formulation according to Claim 80, comprising the steps:

- producing a homogeneous mixture of the active principle and the excipient, containing at least 50% of active principle;

- subjecting the homogeneous mixture of a high compression;

- grinding the compressed articles obtained; and

- putting into a form suitable for administration.

95. (currently amended) A solid or semi-solid delayed-release formulation, adapted for implantation in a deposit site of a body via an invasive device containing at least one active principle and a biodegradable excipient, wherein the excipient is a polylactide-glycolide (PLGA) copolymer, the active principle is a proteic or peptidic active principle not being insulin, wherein the concentration of active principle is ~~between 40 and 100%~~ above 50% and less than or equal to 80%, and wherein the excipient does not form a matrix containing the active principle, whereby the release profile of the active principle is substantially constant and the duration of release is substantially greater *in vivo* than in a physiological aqueous medium *in vitro*.

96. (previously presented) The delayed-release formulation according to claim 95, wherein the amount of active

principle is limited for a local pharmaceutical activity on said deposit site.

97. (previously presented) The delayed-release formulation according to claim 95, wherein said delayed-release formulation is a non-dispersed solid or semi-solid formulation.

98. (previously presented) The delayed-release formulation according to claim 95, wherein said delayed-release formulation is a solid or a semi-solid dispersed formulation.

99. (currently amended) A solid delayed-release formulation for parenteral administration through an invasive device delivering said formulation in a body comprising a homogeneous mixture of an active principle wherein the active principle selected from the group consisting of triptorelin acetate, lanreotide acetate, triptorelin, gosserelin, leuprorelin, buserelin, triptorelin salts, gosserelin salts, leuprorelin salts, buserelin salts, a compound having an LH-RH activity, an LH-RH antagonist, a GPIIb/IIIa antagonist, a compound having an activity similar to a GPIIb/IIIa antagonist, erythropoietin or one of its analogues, an erythropoietin analogue, an α interferon, β interferon, γ interferon, somatostatin, a somatostatin derivative or analogue, a growth hormone, a growth hormone release factor, an epidermal growth factor, a melanocyte-stimulating hormone, a thyrotropin release hormone, a salt of a thyrotropin release hormone or one of its salts or derivatives, a thyroid-stimulating hormone (TSH), a

luteinizing, a follicle-stimulating hormone (FSH), insulin, a parathyroid hormone or one of its derivatives, a hydrochloride of lysozyme, human PTH hormone, vasopressin or one of its derivatives, oxytocin, calcitonin, a calcitonin derivative, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human placenta lactogen, human chorionic gonadotropin, enkephalin, colony-stimulating factor, and interleukin, an enkephalin derivative, kyotorphin, an interleukin, tuftsin, thymopoietin, thymosthymine, thymic humoral factor, thymic serum factor, a derivative of thymic serum factor, thymosin, thymic factor X, tumor necrosis factor, motilin, bombesin, a bombesin derivative, prolactin, neurotensin, dynorphin, careulein, substance P, urokinase, asparginase, bradykinin, kallikren, nerve growth factor, a ~~bloдd~~ blood coagulation factor, polymixin B, colistin, gramicin, bacitracin, a peptide stimulating protein synthesis, an antagonist of endothelin, a vaso-active intestinal polypeptide, adrenocorticotropic hormone, a platelet-derived growth factor, a bone morphogenic protein, and a gastric inhibitor polypeptide, in a non-dispersed state forming a continuous phase of which at least one part is in direct contact with the exchange surface of the formulation and of the exterior biological medium, and of a biodegradable biocompatible excipient, in which the quantity of active principle is ~~at least 50%~~ above 50% and less than or equal to 80% by weight with respect to the total weight of the

formulation, and having a release profile which is independent of the composition of the excipient, of the molecular weight of the excipient or of the active principle/excipient weight ratio, the release profile being substantially dependent on the total quantity of active principle present in the formulation.

100. (currently amended) A solid or semi-solid delayed-release formulation, adapted for implantation in a deposit site of a body via an invasive device containing at least one active principle and a biodegradable excipient, wherein the excipient is a polylactide-glycolide (PLGA) copolymer, the active principle selected from the group consisting of triptorelin acetate, lanreotide acetate, triptorelin, gosserelin, leuprorelin, buserelin, triptorelin salts, gosserelin salts, leuprorelin salts, buserelin salts, a compound having an LH-RH activity, an LH-RH antagonist, a GPIIb/IIIa antagonist, a compound having an activity similar to a GPIIb/IIIa antagonist, erythropoietin or one of its analogues, an erythropoietin analogue, an α interferon, β interferon, γ interferon, somatostatin, a somatostatin derivative or analogue, a growth hormone, a growth hormone release factor, an epidermal growth factor, a melanocyte-stimulating hormone, a thyrotropin release hormone, a salt of a thyrotropin release hormone or one of its salts or derivatives, a thyroid-stimulating hormone (TSH), a luteinizing, a follicle-stimulating hormone (FSH), insulin, a parathyroid hormone or one of its derivatives, a hydrochloride of lysozyme, human PTH

hormone, vasopressin or one of its derivatives, oxytocin, calcitonin, a calcitonin derivative, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human placenta lactogen, human chorionic gonadotropin, enkephalin, colony-stimulating factor, and interleukin, an enkephalin derivative, kyotorphin, an interleukin, tuftsin, thymopoietin, thymosthymine, thymic humoral factor, thymic serum factor, a derivative of thymic serum factor, thymosin, thymic factor X, tumor necrosis factor, motilin, bombesin, a bombesin derivative, prolactin, neurotensin, dynorphin, careulein, substance P, urokinase, asparginase, bradykinin, kallikren, nerve growth factor, a ~~bledd~~ blood coagulation factor, polymixin B, colistin, gramicin, bacitracin, a peptide stimulating protein synthesis, an antagonist of endothelin, a vaso-active intestinal polypeptide, adrenocorticotropic hormone, a platelet-derived growth factor, a bone morphogenic protein, and a gastric inhibitor polypeptide, wherein the concentration of active principle is ~~between 40 and 100%~~ above 50% and less than or equal to 80%, and wherein the excipient does not form a matrix containing the active principle, whereby the release profile of the active principle is substantially constant and the duration of release is substantially greater *in vivo* than in a physiological aqueous medium *in vitro*.

101. (new) Formulation according to claim 80, wherein the active principle concentration is equal or above 51% and less than or equal to 80%.

102. (new) Formulation according to claim 80, wherein the active principle concentration is equal or above 60% and less than or equal to 80%.

103. (new) Formulation according to claim 80, wherein the active principle concentration is equal or above 70% and less than or equal to 80%.

104. (new) Formulation according to claim 80, wherein the active principle is LHRH.

105. (new) Formulation according to claim 80, wherein the active principle is an LHRH analog.

106. (new) Formulation according to claim 105, wherein the active principle is Triptoreline.

107. (new) Formulation according to claim 105, wherein the active principle is a Triptoreline salt.

108. (new) Formulation according to claim 107, wherein the active principle is Triptoreline acetate.

109. (new) Formulation according to claim 80, wherein the formulation has a thin and elongated form with a diameter equal or less than 3 mm.

110. (new) Formulation according to claim 109, wherein the formulation has a thin and elongated form with a diameter equal or less than 2.5 mm.

111. (new) Formulation according to claim 109, wherein the formulation has a thin and elongated form with a diameter equal or less than 2 mm.

112. (new) Formulation according to claim 109, wherein the formulation has a thin and elongated form with a diameter equal or less than 1 mm.

113. (new) Formulation according to claim 109, wherein the formulation has a thin and elongated form with a diameter of the order of 0.1 mm.

114. (new) Formulation according to claim 80, wherein the formulation has a thin and elongated form with a length of several centimeters.

115. (new) Formulation according to claim 114, wherein the formulation has a thin and elongated form with a length of less than 3 cm.

116. (new) Formulation according to claim 114, wherein the formulation has a thin and elongated form with a length of less than 2 cm.

117. (new) Formulation according to claim 95, wherein the active principle concentration is equal or above 51% and less than or equal to 80%.

118. (new) Formulation according to claim 95, wherein the active principle concentration is equal or above 60% and less than or equal to 80%.

119. (new) Formulation according to claim 95, wherein the active principle concentration is equal or above 70% and less than or equal to 80%.

120. (new) Formulation according to claim 95, wherein the active principle is LHRH.

121. (new) Formulation according to claim 95, wherein the active principle is an LHRH analog.

122. (new) Formulation according to claim 121, wherein the active principle is Triptoreline.

123. (new) Formulation according to claim 121, wherein the active principle is a Triptoreline salt.

124. (new) Formulation according to claim 123, wherein the active principle is Triptoreline acetate.

125. (new) Formulation according to claim 95, wherein the formulation has a thin and elongated form with a length of several centimeters.

126. (new) Formulation according to claim 125, wherein the formulation has a thin and elongated form with a length of less than 3 cm.

127. (new) Formulation according to claim 125, wherein the formulation has a thin and elongated form with a length of less than 2 cm.